Tenaris (TS) Stock
Key stats
- Market cap
- $30.90B
- Volume
- Loading
- 52-week high
- $64.60
- 52-week low
- $37.69
- EPS vs analyst estimate
- +13.3%Q3 FY25 · $0.85 vs $0.75
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with TS
Recent news

Tenaris Q2 Earnings Call Highlights
Tenaris Q2 Earnings Call Highlights
TS

Compared to Estimates, Tenaris (TS) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Tenaris (TS) Q2 Earnings: A Look at Key Metrics
TS

Why Tenaris S.A. (TS) is a Great Dividend Stock Right Now
Why Tenaris S.A. (TS) is a Great Dividend Stock Right Now
TS

Tenaris S.A. (TS) Could Be a Great Choice
Tenaris S.A. (TS) Could Be a Great Choice
TS
Technical indicators
- RSI 14
- 60.53
- MACD 12/26/9
- 0.64
- EMA 9 of MACD
- 0.53
- MACD histogram
- 0.11
- SMA 50
- $57.41
- Price above SMA 50
- EMA 50
- $57.72
- Price above EMA 50
- SMA 200
- $56.77
- Price above SMA 200
- EMA 200
- $54.50
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
The market is expecting earnings per share of $0.80 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Tenaris Q2 Earnings Call Highlights
Tenaris Q2 Earnings Call Highlights
TS

Compared to Estimates, Tenaris (TS) Q2 Earnings: A Look at Key Metrics
Compared to Estimates, Tenaris (TS) Q2 Earnings: A Look at Key Metrics
TS

Why Tenaris S.A. (TS) is a Great Dividend Stock Right Now
Why Tenaris S.A. (TS) is a Great Dividend Stock Right Now
TS

Tenaris S.A. (TS) Could Be a Great Choice
Tenaris S.A. (TS) Could Be a Great Choice
TS

NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
TS

Why Tenaris S.A. (TS) is a Great Dividend Stock Right Now
Why Tenaris S.A. (TS) is a Great Dividend Stock Right Now
TS

Why Tenaris S.A. (TS) is a Top Dividend Stock for Your Portfolio
Why Tenaris S.A. (TS) is a Top Dividend Stock for Your Portfolio
TS

Tenaris (TS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Tenaris (TS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
TS

Exploring Analyst Estimates for Tenaris (TS) Q1 Earnings, Beyond Revenue and EPS
Exploring Analyst Estimates for Tenaris (TS) Q1 Earnings, Beyond Revenue and EPS
TS

Tenaris S.A. (TS) Is Up 7.55% in One Week: What You Should Know
Tenaris S.A. (TS) Is Up 7.55% in One Week: What You Should Know
TS
About Tenaris
Tenaris is the leading manufacturer of pipes and related services for the world's energy industry and certain other industrial applications. Our manufacturing system integrates steelmaking, pipe rolling and forming, heat treatment, threading and finishing across 16 countries. We also have an R&D network focused on enhancing our product portfolio and improving our production processes.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Gabriel Podskubka | Chief Executive Officer | 1974 |
| Mr. Carlos Gomez Alzaga | Chief Financial Officer | 1971 |
| Mr. Lucas Pigliacampo | Chief Technology Officer | 1973 |
| Mr. Luis Scartascini | Chief Human Resources Officer | 1974 |
| Mr. Sergio de la Maza | President of Mexico | 1956 |
| Mr. Guillermo Gabriel Moreno | President of U.S.A | 1965 |
| Mr. Gabriel Casanova | Chief Supply Chain Officer | 1959 |
| Mr. Michele Della Briotta | President of Europe | 1973 |
| Mr. Antonio Caprera | Chief Industrial Officer | 1961 |
| Mr. Andrea Previtali | President of Southern Cone | 1973 |
Fundamentals
Valuation
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 60.53
- MACD 12/26/9
- 0.64
- EMA 9 of MACD
- 0.53
- MACD histogram
- 0.11
- SMA 50
- $57.41
- Price above SMA 50
- EMA 50
- $57.72
- Price above EMA 50
- SMA 200
- $56.77
- Price above SMA 200
- EMA 200
- $54.50
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $65.00
- Average
- $72.75
- High
- $88.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -15.7 | +6.2 | ||||||||||
| 2022 | +11.8 | +0.1 | +17.8 | -1.7 | +10.5 | -23.8 | +10.0 | +0.3 | -4.0 | +12.7 | +8.9 | +3.7 |
| 2023 | +5.7 | -4.8 | -15.7 | -2.8 | -14.1 | +16.6 | +12.1 | -5.0 | -2.2 | +2.6 | +8.9 | -0.3 |
| 2024 | -7.9 | +10.0 | +10.5 | -16.5 | -0.8 | -5.5 | +3.6 | +3.2 | +8.5 | +1.8 | +15.4 | -1.8 |
| 2025 | +0.3 | +0.2 | +5.5 | -15.6 | +2.1 | +5.9 | -5.5 | +4.4 | +0.6 | +7.7 | -1.3 | -5.2 |
| 2026 | +13.4 | +21.8 | +6.6 | +10.3 | -4.3 | -11.4 | +5.8 | -2.2 | -2.5 | +8.4 | +5.6 |



